Unique ID issued by UMIN | UMIN000012559 |
---|---|
Receipt number | R000014663 |
Scientific Title | The pilot study on surgical safety after neoadjuvant chemotherapy of mFOLFOX6 for locally advanced rectal cancer. |
Date of disclosure of the study information | 2013/12/14 |
Last modified on | 2020/09/28 17:17:42 |
The pilot study on surgical safety after neoadjuvant chemotherapy of mFOLFOX6 for locally advanced rectal cancer.
The pilot study on surgical safety after neoadjuvant chemotherapy for locally advanced rectal cancer.
The pilot study on surgical safety after neoadjuvant chemotherapy of mFOLFOX6 for locally advanced rectal cancer.
The pilot study on surgical safety after neoadjuvant chemotherapy for locally advanced rectal cancer.
Japan |
locally advanced rectal cancer
Gastrointestinal surgery |
Malignancy
NO
The aim is to evaluate the surgical safety after four courses mFOLFOX6 as neoadjuvant chemotherapy for locally advaced rectal cancer.
Safety
Confirmatory
Others
Phase II
percentage of postoperative complications
Response rate by preoperative chemotherapy, the safety of preoperative chemotherapy, local recurrence rate, disease-free survival
Interventional
Single arm
Non-randomized
Open -no one is blinded
Uncontrolled
1
Treatment
Medicine |
preoperative chemotherapy (4 courses of mFOLFOX6)
20 | years-old | <= |
75 | years-old | >= |
Male and Female
1. The cases histologically diagnosed as rectal cancer by endoscopic biopsy.
2. clinical stage-II or III by preoperative imaging.
3. The main occupation of the primary tumor site is located upper of lower rectum.
4. The age is 20 years old and older and under 75 years old.
5. Performance Status(ECOG) is 0 or 1.
6. No history of surgical treatment for primary tumor.
7. Cases without a history of chemotherapy, radiation, and so on.
8. Cases of major organ function is maintained.
1. Double cancer
2. Pregnant or lactating women.
3. Patients with a history of colorectal cancer(Excluding mucosal cancer).
4. Patients with peripheral sensory neuropathy(CTCAE v4.0> Grade 1).
5. Patients with infectious disease requiring systemic therapy.
6. Patients with uncontrolable cardiovascular disease.
7. Patients with a history of mental disorder.
45
1st name | |
Middle name | |
Last name | Akinobu Taketomi |
Hokkaido University Graduate School of Medicine
Gastroenterological Surgery I
North15 West7, Kita-ku, Sapporo, Hokkaido, Japan
011-706-5927
taketomi@med.hokudai.ac.jp
1st name | |
Middle name | |
Last name | Norihiko Takahashi |
Hokkaido University Hospital
Gastroenterological Surgery I
North15 West7, kita-ku, Sapporo, Hokkaido, Japan
011-706-5927
noripiko@med.hokudai.ac.jp
Gastroenterological Surgery I, Hokkaido University Graduate School of Medicine
Hokkaido University Hospital
Other
NO
2013 | Year | 12 | Month | 14 | Day |
Partially published
DOI: 10.1007/s00595-019-01788-8
41
Surgical morbidity (grade 3 or above) occurred in 4 patients (10.5%). Surgery after four courses of mFOLFOX6 chemotherapy can be a safe and promising strategy for patients with locally advanced rectal cancer.
2020 | Year | 09 | Month | 28 | Day |
2019 | Year | 05 | Month | 05 | Day |
Main results already published
2013 | Year | 12 | Month | 12 | Day |
2020 | Year | 11 | Month | 11 | Day |
2013 | Year | 12 | Month | 16 | Day |
2020 | Year | 09 | Month | 05 | Day |
none remarks
2013 | Year | 12 | Month | 12 | Day |
2020 | Year | 09 | Month | 28 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000014663